Used in research settings as a selective NOTCH inhibitor, particularly in oncology studies focusing on cancers driven by NOTCH signaling pathways. Shows potential in preclinical models for treating hematologic malignancies and solid tumors. Investigated for its ability to block oncogenic NOTCH activation without affecting non-activated NOTCH, which may reduce side effects compared to earlier generation inhibitors. Currently part of experimental therapies in early-stage clinical trials.